Core Viewpoint - The company Yiming Anke has decided to terminate its licensing agreement with Axion for two drug candidates, IMM2510 and IMM27M, and will reclaim all rights previously granted to Axion, including global development and commercialization rights outside Greater China [1] Group 1: Licensing Agreement Details - The initial licensing agreement with Axion began in August 2024, with a collaboration amount exceeding $2 billion [1] - Yiming Anke has received a total of $35 million in upfront and milestone payments from Axion prior to the termination of the agreement [1] Group 2: Reasons for Termination - The CEO of Yiming Anke stated that the collaboration with Axion had been pleasant, but the slow clinical progress due to funding constraints led to the decision to reclaim the rights [1] - Shareholders had been advising the company to reclaim the overseas rights for the two products, making this an opportune moment for the company [1] Group 3: Product Information - IMM2510 is a PD-L1/VEGF bispecific antibody, which is a significant target in tumor immunotherapy, and its potential to disrupt the PD-1 market is highly anticipated [2] - The market for PD-1/VEGF bispecific antibodies has seen increased activity since 2024, with notable deals such as the $1.25 billion upfront payment received by a competitor for a similar product [2] Group 4: Future Plans - Yiming Anke expressed confidence in the therapeutic potential of IMM2510 and IMM27M and aims to accelerate their clinical development [3] - The company plans to seek new business development partnerships with large multinational pharmaceutical companies, which will be simplified by reclaiming the rights from Axion [3]
创新药出海热潮下，这家药企为何收回对外授权